Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion

Journal of Digestive Diseases

Volumn 14, Issue 8, 2013, Pages 446-450

  Cao, Zhen Huan ^a   Ma, Li Na ^a   Zhang, Hong Wei ^a   Liu, Ya Li ^a   Chen, Xin Yue ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; Combination therapy; Hepatitis B e antigen; Lamivudine; Peginterferon alfa 2a; Seroconversion

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; APPETITE; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FOLLOW UP; GINGIVA BLEEDING; HEPATITIS B; HUMAN; HYPERTHYROIDISM; MALE; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION;

CHRONIC HEPATITIS B; COMBINATION THERAPY; HEPATITIS B E ANTIGEN; LAMIVUDINE; PEGINTERFERON ALFA-2A; SEROCONVERSION;

ADENINE; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880027204     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12065     Document Type: Article

References (19)

1. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Chin J Gastroenterol 2011; 16: 351-366 (in Chinese).
2. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000; 61: 362-366.
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
5. Sonneveld MJ, Janssen HL. Pros and cons of peginterferon versus nucleos(t)ide analogues for treatment of chronic hepatitis B. Curr Hepat Rep 2010; 9: 91-98.
6. Marcellin P, Heathcote EJ, Buti M etal. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455.
7. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int 2009; 29 Suppl 1: 1-8.
8. Buster EH, Flink HJ, Cakaloglu Y etal. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b. Gastroenterology 2008; 135: 459-467.
9. Lau GK, Piratvisuth T, Luo KX etal; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695.
10. Marcellin P, Lau GK, Bonino F etal; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217.
11. Marcellin P, Bonino F, Lau GK etal; Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-2179.e4.
12. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009; 49: S103-111.
13. Chen X, Cao Z, Liu Y etal. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog. J Gastroenterol Hepatol 2012; 27: 481-486.
14. Niederau C, Heintges T, Lange S etal. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427.
15. Janssen HL, van Zonneveld M, Senturk H etal; HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129.
16. Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57: 84-90.
17. Moucari R, Korevaar A, Lada O etal. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50: 1084-1092.
18. Yuen MF, Wong DK, Fung J etal. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-1199.
19. van Zonneveld M, Honkoop P, Hansen BE etal. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-810.